Stockpolly
Search
Delisting risk
NIKI · NASDAQ · Biotechnology

Niki BioSolutions (NIKI)

Develops blood-based brain-health diagnostics and provides molecular biomarker testing services.

$7.00
Pre-market+0.39 (+5.90%)
At close$6.61(−0.15%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY20Dec 2020Q2 FY21Jun 2021Q4 FY21Dec 2021Q2 FY22Jun 2022Q4 FY22Dec 2022Q2 FY23Jun 2023Q4 FY23Dec 2023Q2 FY24Jun 2024Q4 FY24Dec 2024Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025
Revenue111110000000
Cost of revenue111111000000
Gross profit−1−1−1−1−1−1000000
119989642−1011
Research & development755443320000
444443110101
Selling & marketing−30−20−20000000
General & administrative706060000001
Other expenses000000−10−1000
Operating income−12−9−10−8−9−7−4−30000
24−8060060−10−10
Interest income000000000000
Interest expense−3,6990−3,699000000000
Other non-operating income1470−600−600011
Income before tax12−17−10−3−9−72−3−10−10
Net income from continuing operations12−17−10−3−9−72−3−10−10
Other adjustments011111000000
Net income13−16−9−2−8−53−3−10−10
EPS, basic$390.00−$469.10−$251.60−$52.80−$221.60−$142.50$51.00−$49.50−$14.60−$6.20−$8.50−$4.20
EPS, diluted$390.00−$469.10−$251.60−$52.80−$221.60−$142.50$51.00−$49.50−$14.60−$6.20−$8.50−$4.20
Weighted average shares, basic000000000000
Weighted average shares, diluted000000000000
EBITDA13−16−9−2−8−63−200−1−1
Depreciation & amortization111111000000
EBIT12−17−10−3−9−72−300−1−1